By Pat Anson, Editor
The Food and Drug Administration has informed a British pharmaceutical company that it will not stop other drug makers from producing generic versions of Suboxone tablets, one of its top selling products. The move is a serious blow to Reckitt Benckiser’s efforts to maintain its monopoly of Suboxone, which generates sales of about $1.5 billion annually.
Two New Jersey based generic drug makers said they had obtained FDA approval and would immediately begin selling generic versions of buprenorphine, which is more widely known as Suboxone. The drug is increasingly being used to treat addiction to heroin and opioid painkillers such as Vicodin and OxyContin.
Read more at National Pain Report.